What insurance policy changes affect code M26.69?

There are 6 tracked policy changes affecting code M26.69, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M26.69?

Payers that have issued tracked updates for code M26.69 include: Aetna.

How do I get notified when code M26.69 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M26.69. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M26.69?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

M26.69 Insurance Policy Changes

ICD-10 M26.69 is officially defined as "Other specified disorders of temporomandibular joint." code M26.69 is referenced in 6 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M26.69 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 18, 2026Medium impact
Manipulation Under General Anesthesia (CPB 0204, reviewed 2026-03-25)
Aetna considers manipulation under anesthesia (MUA) medically necessary for arthrofibrosis of the knee following total knee arthroplasty, knee surgery, or fracture, for chronic refractory frozen shoulder (adhesive capsulitis), and for temporomandibular joint disorders. Spinal manipulation under general MUA is considered experimental, investigational, or unproven, and CPT 22505 is not covered for the indications listed in the policy. The policy does not apply to examinations under anesthesia, or to setting fractures or complete joint dislocations under anesthesia.
Aetna · Identified Aug 14, 2026Medium impact
Jaw Motion Rehabilitation Systems (CPB 0412, reviewed 2026-06-30)
Aetna considers jaw motion rehabilitation systems, such as the Therabite Jaw Motion Rehabilitation System and the OraStretch press, medically necessary to treat mandibular hypomobility caused by radiation in persons with head and neck cancers. These systems are considered experimental, investigational, or unproven for all other indications, including trismus, closed lock, orofacial pain, non-surgical temporomandibular joint dysfunction, stroke, and Treacher Collins syndrome. Some plans exclude coverage of jaw stretch devices as equipment available over the counter without a prescription.
Aetna · Identified Aug 14, 2026Medium impact
Eagle's and Ernest Syndrome (CPB 0400, reviewed 2026-06-30)
Aetna's Clinical Policy Bulletin 0400 considers styloidectomy medically necessary for Eagle's syndrome only when specific criteria are met, with separate criteria for the non-vascular form and the vascular form linked to carotid artery dissection. Radiofrequency thermoneurolysis is considered experimental, investigational or unproven for Eagle's and Ernest syndromes, and styloidectomy for jugular vein stenosis, for carotid stenosis without dissection, and for other listed indications such as tinnitus, headache and neck pain is also considered experimental, investigational or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Phonophoresis (CPB 0210, reviewed 2026-03-27)
Aetna considers phonophoresis experimental, investigational, or unproven for all indications, including adhesive capsulitis, carpal tunnel syndrome, knee osteoarthritis, low back pain, neck pain, sinusitis, chronic obstructive pulmonary disease, and venous and diabetic ulcers, because its effectiveness has not been established. Controlled clinical trials have failed to demonstrate that phonophoresis increases the rate or extent of absorption of analgesics and anti-inflammatory agents. Bee venom phonophoresis and Contractubex phonophoresis are listed as not covered for the indications in the policy.
Aetna · Identified Aug 12, 2026Medium impact
Biofeedback (CPB 0132, reviewed 2026-07-16)
Aetna considers biofeedback medically necessary for cancer pain, chronic constipation secondary to dyssynergic defecation as confirmed by anorectal manometry, fecal incontinence, irritable bowel syndrome, levator ani syndrome, migraine and tension headaches, refractory severe subjective tinnitus, temporomandibular joint syndrome, urinary incontinence, and neuromuscular rehabilitation of stroke and traumatic brain injury. Biofeedback is considered not medically necessary when used to improve emotional and physical health in non-diseased persons. EEG biofeedback is considered experimental, investigational, or unproven for migraine and tension headache, and several listed uses are experimental, including amygdala-related EEG neurofeedback for PTSD, HeartMath HRV biofeedback for headaches, InTandem for walking in chronic stroke, and surface EMG biofeedback for chronic ankle instability. Some Aetna plans exclude coverage of biofeedback.
Aetna · Identified Aug 12, 2026Medium impact
Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)
Clinical Policy Bulletin 0784 considers the following experimental, investigational, or unproven because their effectiveness has not been established: autologous blood injection and platelet-poor or platelet-rich plasma injection for all indications, plus specific listed uses of autologous platelet gel, adipose-tissue-derived stem cell injections, autologous fat injection and other blood-derived products. Listed uses include platelet-rich plasma for rotator cuff injuries, osteoarthritis and plantar fasciitis, autologous platelet gel after total knee arthroplasty and for diabetic foot ulcer, and autologous fat injection for carpometacarpal arthritis of the thumb and velopharyngeal insufficiency. The policy also lists CPT, HCPCS and ICD-10 codes as not covered for the indications it lists.

Watch M26.69

Get one email when a payer policy names M26.69, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Manipulation Under General Anesthesia (CPB 0204, reviewed 2026-03-25)

Jaw Motion Rehabilitation Systems (CPB 0412, reviewed 2026-06-30)

Eagle's and Ernest Syndrome (CPB 0400, reviewed 2026-06-30)

Phonophoresis (CPB 0210, reviewed 2026-03-27)

Biofeedback (CPB 0132, reviewed 2026-07-16)

Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)

What insurance policy changes affect code M26.69?

Which payers have updated policy for code M26.69?

How do I get notified when code M26.69 policy changes?

Why do payers change policies for code M26.69?